Research Article
Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
Table 2
Demographic and clinical characteristics of patients of therapeutic dose group of rivaroxaban compared to warfarin.
| | Patients’ characteristics | Therapeutic dose group of rivaroxaban | Warfarin
| value | | () | () |
| | Mean age ± SD | 69.94 ± 15.24 | 71.35 ± 13.09 | 0.7088 |
| | Age ≥ 65 | 59 (67.82%) | 104 (67.97%) | 0.98 | | Age < 65 | 28 (32.18%) | 49 (32.03) |
| | Gender | | | | | Female | 39 (44.83%) | 83 (54.25%) | 0.1605 | | Male | 48 (55.17%) | 70 (45.75%) |
| | Ethnic group | | | | | White | 66 (75.86%) | 133 (86.93%) | 0.285 | | AA | 12 (13.79%) | 4 (2.61%) | | Others | 9 (10.35%) | 16 (10.46%) |
| Indication for
drug | | | | | AF | 67 (77.01%) | 93 (60.78%) | < | | VTE treatment | 12 (13.79%) | 56 (36.60%) | | VTE prophylaxis | 2 (2.30%) | 2 (1.31%) | | Other | 6 (6.90%) | 2 (1.31%) |
| | Mean duration being on drug (Days) ± SD | 125.30 ± 131.00 | 252.95 ± 167.91 | < |
| | Duration ≤40 days | 31 (35.63%) | 16 (10.46%) | < |
| | Concomitant with aspirin | 44 (50.58%) | 63 (41.18%) | |
| | Concomitant with thienopyridine | 11 (12.64%) | 27 (17.65%) | 0.3074 |
| | Dual antiplatelet agents | 8 (9.20%) | 15 (9.80%) | 0.8776 |
| | Concomitant with NSAIDs | 8 (9.20%) | 7 (4.58%) | 0.2187 |
| | Hb < 12 | 27 (32.14%) | 54 (35.29%) | 0.0803 | | Missing data | 3 | 0 |
| | Cr > 1.5 | 5 (5.95%) | 15 (9.80%) | 0.1134 | | Missing data | 3 | 0 |
| | GFR ≤ 30 | 1 (1.20%) | 6 (3.92%) | 0.5645 | | Missing data | 3 | 0 |
| | ALT > 40 | 8 (10.26%) | 28 (20%) | 0.1081 | | Missing data | 9 | 13 |
| | BMI | | | | | <18.5 | 3 (3.45%) | 0 (0%) | 0.4152 | | 18.5–24.9 | 21 (24.14%) | 35 (22.88%) | | >25 | 63 (72.41%) | 118 (77.12%) | | Missing data | 0 | 0 |
| | Previous GI bleeding | 4 (4.60%) | 15 (9.80%) | 0.1551 |
|
|
AA: African American, AF: atrial fibrillation, ALT: alanine aminotransferase, BMI: body mass index, Cr: creatinine, GFR: glomerular filtration rate, GI: gastrointestinal, Hb: hemoglobin, NSIADs: nonsteroidal anti-inflammatory drugs, and VTE: venous thromboembolism events. Signifying statistical significant values.
|
